<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Rhythm Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc</link>
<description>Latest news and press releases for Rhythm Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/rhythm-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bc3f78dffbe2df116af9.webp</url>
<title>Rhythm Pharmaceuticals Inc</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc</link>
</image>
<item>
<title>Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-tuesday-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-tuesday-may-5-2026</guid>
<pubDate>Thu, 09 Apr 2026 12:00:00 GMT</pubDate>
<description>BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Tuesday, May 5, 2026 to report its first quarter 2026 financial results and provide a corporate update. Also today, Rhythm announced that Hunter Smith, Chief Financial Officer, will parti</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces Changes to Board of Directors</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-changes-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-changes-to-board-of-directors</guid>
<pubDate>Fri, 03 Apr 2026 04:00:00 GMT</pubDate>
<description>-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-receives-positive-chmp-opinion-for-imcivreer-setmelanotide-for-the-treatment-of-obesity-and-control-of-hunger-in-patients-with-acquired-hypothalamic-obesity-due-to-hypothalamic-injury-or-impairment</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-receives-positive-chmp-opinion-for-imcivreer-setmelanotide-for-the-treatment-of-obesity-and-control-of-hunger-in-patients-with-acquired-hypothalamic-obesity-due-to-hypothalamic-injury-or-impairment</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:</description>
</item>
<item>
<title>PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/pantherxr-rare-selected-by-rhythm-pharmaceuticals-inc-as-the-exclusive-us-specialty-pharmacy-for-the-expanded-indication-for-imcivreer-setmelanotide</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/pantherxr-rare-selected-by-rhythm-pharmaceuticals-inc-as-the-exclusive-us-specialty-pharmacy-for-the-expanded-indication-for-imcivreer-setmelanotide</guid>
<pubDate>Fri, 20 Mar 2026 16:58:00 GMT</pubDate>
<description>PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), as the exclusive U.S. Pharmacy distribution partner for the expanded indication of IMCIVREE® (setmelanotide) for adults and children 4 years of age and older living with acquired hypothalamic obesity.1</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-fda-approval-of-imcivreer-setmelanotide-for-patients-with-acquired-hypothalamic-obesity</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-fda-approval-of-imcivreer-setmelanotide-for-patients-with-acquired-hypothalamic-obesity</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-topline-results-from-phase-3-emanate-trial</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-topline-results-from-phase-3-emanate-trial</guid>
<pubDate>Mon, 16 Mar 2026 20:01:00 GMT</pubDate>
<description>-- Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heterozygous variant of the POMC/PCSK1 and SRC1 (NCOA1) genes at 52 weeks – -- Conference call planned for 4:30 p.m. ET today – BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of pati</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-additional-positive-data-from-phase-3-transcend-trial-of-setmelanotide-in-patients-with-acquired-hypothalamic-obesity</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-additional-positive-data-from-phase-3-transcend-trial-of-setmelanotide-in-patients-with-acquired-hypothalamic-obesity</guid>
<pubDate>Sun, 01 Mar 2026 17:30:00 GMT</pubDate>
<description>-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- BOSTON, March 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare n</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-update</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for</description>
</item>
<item>
<title>Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-february-26-2026</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Thursday, February 26, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. To access the live conference call, participants may register</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-participation-upcoming-guggenheim-biotech-summit</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-participation-upcoming-guggenheim-biotech-summit</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-preliminary-unaudited-fourth-quarter-and-full-year</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-preliminary-unaudited-fourth-quarter-and-full-year</guid>
<pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
<description>-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11%</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-preliminary-data-exploratory-phase-2-trial-showed</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-preliminary-data-exploratory-phase-2-trial-showed</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled</description>
</item>
<item>
<title>Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announce-preliminary-data-exploratory-phase-2-trial-evaluating</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announce-preliminary-data-exploratory-phase-2-trial-evaluating</guid>
<pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
<description>BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-presentation-four-datasets-obesityweekr-2025-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-presentation-four-datasets-obesityweekr-2025-2025-11</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-fda-extension-review-period-imcivreer-setmelanotide</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-fda-extension-review-period-imcivreer-setmelanotide</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-public-reimbursement-imcivreer-setmelanotide-canada</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-public-reimbursement-imcivreer-setmelanotide-canada</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-reports-third-quarter-2025-financial-results-and-business</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-reports-third-quarter-2025-financial-results-and-business</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>-- Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million -- -- December 20, 2025 PDUFA goal date set for sNDA</description>
</item>
<item>
<title>Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-report-third-quarter-2025-financial-results-tuesday-november-4</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-report-third-quarter-2025-financial-results-tuesday-november-4</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-participation-upcoming-investor-conferences-2025-08</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-participation-upcoming-investor-conferences-2025-08</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity</title>
<link>https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-fda-acceptance-snda-setmelanotide-acquired</link>
<guid isPermaLink="true">https://6ix.com/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-fda-acceptance-snda-setmelanotide-acquired</guid>
<pubDate>Wed, 20 Aug 2025 04:00:00 GMT</pubDate>
<description>– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency</description>
</item>
</channel>
</rss>